Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





New Fast and Easy-to-Perform COVID-19 Test Detects New Emerging SARS-CoV-2 Variants in Just Over One Hour

By HospiMedica International staff writers
Posted on 10 Mar 2021
A new rapid COVID-19 test can detect all three of the rapidly spreading variants of the SARS-CoV-2 virus in a little over one hour – much shorter than the three to five days required by current tests, which can also be more technically difficult and expensive to perform.

The fast and easy-to-perform test developed by researchers at Rutgers University (New Brunswick, NJ, USA) can help the world identify hot spots of transmission. More...
The Rutgers researchers designed and clinically validated the test, which is the first to use “sloppy molecular beacon probes,” which are highly sensitive and specific DNA sequences used to detect frequent mutations in organisms.

The new rapid test is easy to set up and can be adapted for labs that use varying types of equipment and methods. The Rutgers researchers said users are free to use the test as described or modify it as needed, although they strongly suggest that additional validation be done for any test modifications. The researchers are also working to expand their test to more precisely differentiate among the three main viral variants and they expect to release a new and larger test menu along with supporting evidence in the next several weeks. Additional test modifications will be released in the future as additional variants emerge.

“This rapid test was developed and tested over a few weeks in a crash program to respond to a serious public health need,” said David Alland, director of the Rutgers New Jersey Medical School (NJMS) Public Health Research Institute and professor and chief of infectious disease at NJMS. “Despite our hurry to get the test completed, it performed extremely well with clinical samples in our initial studies. We are very pleased with these results and we hope that this test will help in the control of the rapidly evolving COVID-19 pandemic.”

Related Links:
Rutgers University


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Bipolar Coagulation Generator
Aesculap
New
Syringes
Prefilled Saline Flush Syringes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.